Literature DB >> 9205069

Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin.

T G O'Brien1, L C Megosh, G Gilliard, A P Soler.   

Abstract

In multistage tumorigenesis models, ornithine decarboxylase (ODC) is usually dysregulated at some point during tumor promotion, an early stage of carcinogenesis. To address the question whether constitutive overexpression of ODC would be a sufficient condition for tumor promotion, mice with high levels of ODC expression targeted to epidermal keratinocytes were used in skin tumorigenesis experiments. Transgenic mice with ODC targeted to hair follicle keratinocytes were much more sensitive than littermate controls to initiation with a single low dose of carcinogen; in fact, such mice no longer required treatment with tumor promoters for tumors to develop. Targeting ODC overexpression to both interfollicular and follicular keratinocytes did not further enhance tumor yield. Our results suggest that most, if not all, target cells for chemical carcinogens in the skin reside in hair follicles, and ODC overexpression is sufficient to activate such cells to expand clonally to form epidermal tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205069

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  64 in total

1.  Deregulation of common genes by c-Myc and its direct target, MT-MC1.

Authors:  Kenneth R Rogulski; Debra E Cohen; David L Corcoran; Panayiotis V Benos; Edward V Prochownik
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

2.  Polyamines regulate gap junction communication in connexin 43-expressing cells.

Authors:  L Shore; P McLean; S K Gilmour; M B Hodgins; M E Finbow
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

3.  Elevated ornithine decarboxylase activity promotes skin tumorigenesis by stimulating the recruitment of bulge stem cells but not via toxic polyamine catabolic metabolites.

Authors:  Candace S Hayes; Karen DeFeo-Mattox; Patrick M Woster; Susan K Gilmour
Journal:  Amino Acids       Date:  2013-07-25       Impact factor: 3.520

4.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

5.  Effect of spermine synthase on the sensitivity of cells to anti-tumour agents.

Authors:  Yoshihiko Ikeguchi; Caroline A Mackintosh; Diane E McCloskey; Anthony E Pegg
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

6.  Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Authors:  Robert J Rounbehler; Weimin Li; Mark A Hall; Chunying Yang; Mohammad Fallahi; John L Cleveland
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

7.  Elevated ornithine decarboxylase levels activate ataxia telangiectasia mutated-DNA damage signaling in normal keratinocytes.

Authors:  Gang Wei; Karen DeFeo; Candace S Hayes; Patrick M Woster; Laura Mandik-Nayak; Susan K Gilmour
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Cancer-relevant biochemical targets of cytotoxic Lonchocarpus flavonoids: a molecular docking analysis.

Authors:  Caitlin E Cassidy; William N Setzer
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

9.  Keratin-6 driven ODC expression to hair follicle keratinocytes enhances stemness and tumorigenesis by negatively regulating Notch.

Authors:  Aadithya Arumugam; Zhiping Weng; Sandeep C Chaudhary; Farrukh Afaq; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2014-08-02       Impact factor: 3.575

10.  Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor.

Authors:  Mark R Burns; Gerard F Graminski; Reitha S Weeks; Yan Chen; Thomas G O'Brien
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.